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INTRODUCTION
Cancer is a disease developed from permanent loss of 
balance between death and life at the intercellular level. 
Abnormal proliferation, ruined tissue, and organ archi-
tecture lead to local and soon after, systemic dysfunc-
tion. Because of rowdy tissue organization, the main 
impression is that tumor grows randomly and with-
out any rules. Today is well recognized that strategies 
employed by tumor at cellular as well as intercellular 
level are fascinating, and altogether demonstrates the 
superiority toward all therapeutic approaches which 
ignored their “higher intelligence” and treat them as 
randomly generated proliferative mass of the cells. 
Their plasticity and an enormous capacity to change 
phenotype and avoid host immune defense became 
more and more powerful through the process of de-
diff erentiation [1]. According to this parameter, tumors 
are classifi ed into grades. So, high-grade tumors are in-
vasive/metastatic and, in general, almost incurable. The 
diff erence in sensitivity to treatment between well dif-
ferentiated and low or non-diff erentiated forms of can-
cer can be explained not only by the cell death resistant 
phenotype of poorly diff erentiated cell subpopulation 
but even more by specifi c intercellular communication 
inside of the heterogeneous tumor mass. Tumor re-
population frequently observed upon the chemo- or 
radiotherapies of metastatic tumors arose as a conse-
quence of this specifi c and complex interplay between 
members of tumor commune [2,3]. Proliferation in 
response to death induction basically compromised 
healing protocols in high-grade tumor treatments [4]. 
As a consequence of this, traditional medicine and al-
ternative approaches, which are not accepted by con-
ventional medicine as legitimate, scientifi cally are very 
frequently explored during the last decades. Numerous 
data generated from investigation of antitumor poten-
tial of diff erent herbs, fractions or isolated compounds 
give to biologist hard but important task – to select the 
most potent between them, to explain how they work 
at the molecular level, defi ne their targets and then as-
sess possibility to improve them and use as a drugs in 
treatment of cancer. For all, scientist and people out of 
the science, the main task remains to understand – how 
people, starting from 4000 years ago were able to rec-
ognize and treat diseases using certain herbs. 
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ALOE VERA- FROM ANCIENT TIME TO DATE
One of the oldest and most powerful plants with extra-
ordinary potential to heal is, for sure, Aloe vera. Its po-
tential to regenerate the wounds, inhibit infl ammation, 
suppress infection, stimulate the clearness of the gut 
and in general bring the refreshment for the whole 
body, and be used for beauty care, as well as preserva-
tion, is described by old civilization such as Sumerian 
and Egyptians, starting from 4000 years BCE [5]. There 
are data indicating that the main motive of Alexander 
the Great for capturing Island of Socotra in the Indian 
Ocean was to come close to the famous Aloe plants 
growing there, required for healing the wounds of sol-
diers [5]. Today, at the market, the most popular pro-
duct made from this herb is aloe gel, which from the 
middle of the last century, became popular nutritional 
drink with a long list of benefi cial eff ects to the health 
maintenance but also in diff erent pathologies. This po-
tent infl uence on human physiology is pivotally ascri-
bed to diff erent carbohydrates but also numerous pro-
teins, lipids, amino acids, vitamins, enzymes, inorganic 
compounds, and small organic molecules present in 
Aloe vera leaf pulp. Polysaccharide fraction is found to 
be very important in the stimulation of innate immu-
nity and regarding this, Aloe vera gel was indicated as 
an immune booster [6]. Synergistic actions of numero-
us other ingredients of Aloe vera leaf extract protect he-
althy tissue from destruction and intoxication triggered 
by the chemotherapy. However, according to double 
edge sword principle, consumption of the gel conco-
mitantly with chemotherapy can be questionable since 
compounds from Aloe vera gel can be cytoprotective 
even for malignant cells, decreasing the eff ects of che-
motherapy.  
In addition to numerous constituents listed above, 
many secondary metabolites anticipated as a product 
of III polyketides (PK) as well as lately discovered nov-
el octaketide synthase, PKS4, and PKS5, were found to 
possess strong biological activities as an anti-infl am-
matory, lipid-lowering, antioxidant, microbicidal and 
laxative [7]. Recently, this kind of molecules became 
the most famous concerning their potent direct anti-
neoplastic eff ects [8–12]. The main merit for the antitu-
mor potential of Aloe vera belongs to one of them-Aloe 
emodin (AE). Even the name suggested that its source 
is exclusively Aloe species, this anthraquinone is found 
in many plants frequently used in folk medicine from 
Asia to Balkan. Among them are A. barbadensis miller, 
rhubarb (Rheum palmatum), buckthorn (Rhamnus fran-
gula), Senna etc. In addition to the direct eff ect on the 
viability of malignant cells, long list of AE biological ef-
fects on mammalian cells, in general, should be taken 
into account when its anticancer features are assessed 
[8]. Additionally, potent infl uence of AE on diff erent 
signaling pathways involved in essential cellular pro-
cesses, multiply refl ected on immune cell-mediated an-
titumor activities basically through changed gene and 
protein expression, as well as the activity of diff erent 
mediators implicated in the transfer of information at 
the intracellular level. According to this, the eff ective-
ness of the drugs applied concomitantly with AE can 
be aff ected. How extreme oscillation in eff ects on tu-
mor cells AE exerts, depending on circumstances, such 
as intercellular contact, the presence of proinfl amma-
tory cytokines and the chemotherapeutic drug will be 
reviewed in this paper.
DIRECT ANTITUMOR EFFECTS OF AE- FROM CELL 
DEATH TO DIFFERENTIATION 
A major criterion for characterization of any com-
pound as antitumor is the ability to induce cell death, 
preferentially apoptosis in transformed cells. Following 
this, AE for sure belongs to this list. It is intensively 
studied on a wide range of tumor cell lines and in ad-
dition to numerous original papers its feature to pro-
mote cell death in diff erent forms is also reviewed. Cell 
cycle arrest and apoptosis as a fi nal outcome are noted 
in various in vitro studies on glioma, melanoma, blad-
der, breast, gastric, oral squamous cell carcinoma, co-
lon, cervical, prostate, leukemia cell lines and even 
those that are resistant to conventional chemothera-
peutic [8,12]. Cell cycle arrest is found to be connected 
with the AE interference with cyclin and cyclin-depen-
dent kinases expression [11,13]. Apoptosis as a result of 
AE treatment, depending on the type of the tumor, has 
been realized through the receptor-mediated or mito-
chondrial pathway, and regarding high correlation 
with oxidative stress, can be the consequence of reac-
tive oxygen species (ROS) production. AE triggered the 
activation of caspase-3, -6, -7, -8 and -9, regulates the 
expression of numerous transcriptional factors like nu-
clear factor kappa B (NF-κB), p53, pro/antiapoptotic 
members of B-cell lymphoma-2 (Bcl-2) family etc., af-
fecting almost all intracellular pathways involved in the 
realization of death program [10–19]. Intensifi ed pro-
duction of ROS upon AE exposure in colon cancer cell 
lines induces endoplasmic reticulum stress character-
ized by glucose-related protein 78, phosphorylated 
protein kinase R-like ER kinase, phosphorylated eu-
karyotic initiation factor-2α expression, and increased 
cytosolic calcium level [17]. Additionally, AE elevated 
the permeability of lysosomal membranes in cervical 
adenocarcinoma HeLa cells, followed by the release of 
cathepsins, showing that the drug initiates lysosomal 
pathway-dependent apoptosis [20]. AE targeted vari-
ous signaling pathways included in tumor cell prolifer-
ation, diff erentiation and death like the extracellu-
lar-signal-regulated kinase (ERK), c-Jun N-terminal 
kinase (JNK), p38, mammalian target of rapamycin/
protein kinase B (mTOR/AKT) etc., revealing its strong 
antitumor competence but also, its potential to aff ect 
diff erent aspects of cell functioning [10,11,15,19]. 
During the last decades, more attention is devoted to 
AE ability to trigger autophagy. Its potential to pro-
mote this process strongly refl ected on its antitumor 
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but, importantly, also protumor activities generated in 
interplay with other agents or molecules. It is docu-
mented that fundamentally autophagy has a bivalent 
role in homeostasis maintains and ballast between 
death and self-renewal. An addition to apoptosis, its 
involvement in drug cytotoxicity realization is recog-
nized as highly important since can vary from “safe” 
mode to being the type of cell death. According to this, 
the defi nition of its contribution to any kind of cancer 
treatment became a very important task. For the fi rst 
time, it was observed that the treatment of glioma cells 
with AE, apart from apoptosis, is tracked with the ap-
pearance of acidic vesicles in the cytoplasm, indicative 
for the autophagy.  Regarding this, we speculated that 
both type of programmed cell death – type I (apopto-
sis) and II (autophagic cell death) were triggered by AE 
[10]. However, AE triggered autophagy as opposed to 
the apoptotic process in concomitant treatment with 
other molecule or agent with apoptosis-inducing po-
tential [21]. So far, only one study showed that AE is 
able to lead to mitotic catastrophe. Treatment of HeLa 
cells with AE resulted in the appearance of multinucle-
ate cells, giant and micronuclear cells. Mitotic index 
was diminished and the prevalence of cells in the 
metaphase was noted [22]. Serious facts about lack of 
success and even contraindications of killing based 
protocols in the treatment of highly invasive tumors, 
underline the advantage of diff erentiation based ther-
apies, even with all diffi  culties in research settings and 
time frames needed for the evidence-based assess-
ment of this kind of approach [23]. The most intriguing 
feature of AE, in this context, is its potential to act as a 
diff erentiation-inducing agent. Conversion of un/low 
diff erentiated malignant phenotype into a more ma-
ture stage might be of great benefi t from multiple 
points of view. First, this phenotype conversion is ac-
companied with the decreased proliferation rate and 
the reversion of the higher grade to lower, less aggres-
sive form. In parallel, the process of change into a more 
mature stage remarkably enhances their sensitivity to 
chemotherapy. This eff ect became profoundly import-
ant in vivo and in the context of high grade, heteroge-
neous tumor mass consisted of tumor cells with diff er-
ent phenotype and level of diff erentiation. Presence of 
“stem” cells is a critical point for undesirable tumor re-
population in reaction to aggressive treatment since 
these cells start to proliferate in response to damage in 
the surrounding [23].   Regarding this, it could be spec-
ulated that AE has the potential to promote diff erenti-
ation and subsequently, minimize tumor tissue prolif-
eration in response to apoptosis induced by itself or 
other agents. Tabalocci et al. found that AE endorsing 
macrophage diff erentiation from a human U937 mono-
blastic leukemia cell line, followed with amplifi ed trans-
glutaminase activity. Therefore, AE can serve as a diff er-
entiation-inducing agent in the treatment of leukemia 
[24]. Beside hematological malignancies, abundant 
evidence in vitro showed its potential to diff erent cell 
lines representing solid cancers. We found that treat-
ment of B16 cells, derived from solid melanoma tumor, 
with AE, resulted in inhibited cellular proliferation, ac-
quisition of fl attened enlarged morphology and at the 
biochemical level, intensifi ed melanin production and 
tyrosinase activity. Such transformed the melanoma 
cells lost their potential to induce tumors in syngeneic 
C57/BL6 animals confi rming once again that AE might 
be useful in diff erentiation based therapy of melanoma 
[11]. Alteration of B16 metastatic clone isolated from 
lung metastasis – B16-F10, by AE was followed with an 
elevation of the activity of the transamidating form of 
TG2 while the invasiveness and production of matrix 
metalloproteinase-9 were inhibited [25]. Similarly, in-
tensifi cation of transamidating activity of transglutam-
inase was found upon the treatment of human mela-
noma SK-MEL-28 and A375 cells. AE signifi cantly 
diminished the proliferation, stemness, and invasive 
potential of melanospheres indicating its activity 
against cancer stem cells [26]. Treatment of rat astrocy-
toma C6 with AE beside apoptotic and autophagic cell 
death resulted in phenotype change of survived cells 
that display elongated morphology accompanied with 
elevated glial fi brillary acidic protein (GFAP) expression. 
While GFAP is well-known marker of astrocyte lineage, 
upregulated expression of this protein clearly indicated 
the process of glioma cell maturation upon AE. Having 
in mind that inhibitor of ERK1/2, PD98059, imitated the 
diff erentiation eff ects of AE on glioma cell without trig-
gering tumor cell death, we concluded that diff erenti-
ation of astrocytoma cells was connected with the in-
hibition of this signaling pathway [10]. There are also 
other types of tumors that underwent diff erentiation in 
the presence of this herbal anthraquinone. It was found 
that cervical carcinoma HeLa and oral KB tumor cells 
displayed a panel of molecules that can be connected 
with diff erentiation. For example, alkaline phosphatase 
activity was increased by AE treatment, while prolifer-
ating cell nuclear antigen (PCNA) expression, cyclin A 
and cyclin-dependent kinase 2 (CDK2) were diminished 
[27,28]. Interestingly but not so surprisingly, AE ability 
to induce diff erentiation and inhibit proliferation of 
gastric cancer cells was synchronized with repression 
of alkaline phosphatase, oppositely to oral cancer cells 
[29]. This cell-specifi c feature of AE to regulate the 
same protein in the opposite manner is also observed 
in the comparative analysis of its infl uence on ERK1/2 
in two diff erent melanoma cell lines. The same dose 
and time frame exposure of less invasive B16 clone and 
the inducible nitric oxide synthases+ (iNOS+) highly in-
vasive amelanotic melanoma cell line-A375 resulted in 
phosphorylation of p44/42 in mirror image mode- 
strong time-dependent inhibition in B16 cells opposite 
to remarkable, also time-dependent, potentiation in 
A375 cell line [11].
Finally, AE interfered with migration, invasion, and 
adhesion of tumor cells infl uencing their dissemina-
tion. AE repressed cancer metastasis through the inhi-
bition of epithelial-mesenchymal transitions transition. 
Exposure of human epidermal growth factor recep-
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tor-2 (HER-2) overexpressing breast cancer cells to AE 
blocked their motility in vitro, suppress YB-1 expression 
through the down-regulation of the intracellular inte-
grin-linked kinase (ILK)/protein kinase B (Akt)/mTOR 
signaling pathway, diminishing further downstream 
HER-2 expression. Moreover, its activity was confi rmed 
in vivo, in xenograft model induced in nude mice [30]. 
In a colon cancer cell, WiDr cells, AE inhibited migra-
tion and invasion induced by the phorbol-12-myris-
tyl-13-acetate. AE targeted a lot of proteins responsible 
for the mentioned eff ects like matrix metalloprotein-
ase (MMP)-2/9, Ras-homologous (Rho) B and vascular 
endothelial growth factor (VEGF) expression. The de-
scribed eff ect might be due to suppressing the nuclear 
translocation and DNA binding of NF-κB [31]. AE also 
inhibits invasion of nasopharyngeal carcinoma cells 
(NPC) by suppressing the expression of MMP-2 via the 
p38, mitogen-activated protein kinase (MAPK)-NF-κB 
signaling pathway [32].  
INTERPLAY WITH MICROENVIRONMENTAL 
FACTORS: FROM ANTI- TO PROTUMOR ACTION
Today is well recognized that micro-environmental fac-
tors are able to transform signals triggered by the drug 
into unexpected and in an unpredictable direction. 
There are more and more data about the sensitive and 
very fragile relationship between signals leading to 
death and those leading to proliferation [2]. Only one 
additional molecule possesses a power to completely 
convert apoptotic into dividing stimulus, and subse-
quently, the outcome of the drug application turns 
into opposite than anticipated.  Numerous molecules 
created with the purpose to induce apoptotic death of 
cancer cells, under certain conditions promoted their 
growth [23]. Plenty of data obtained from clinical trials 
showed that eff ectiveness of tested compounds was 
dramatically lower or even opposite than expected at 
least partly due to this fascinating biological phenom-
enon that extremes- death and life, pro- and anti- al-
ways go together [3]. Data obtained about AE antican-
cer activities greatly illustrated how context defi nes 
the outcome. Many studies describe its potential to 
reduce the number of tumor cells in culture and few of 
them confi rmed this in vivo. Mechanistically, AE works 
as an intercalating agent classifi ed as topoisomerase II 
inhibitor [33]. According to this feature and many other 
data about its infl uence on main signaling pathways 
involved in cell proliferation, death, and diff erentiation, 
AE is characterized as an agent with strong antitumor 
potential.  However, it was clearly showed that even the 
simplest variation in cultivation conditions can radical-
ly change the outcome of the treatment with this com-
pound. Cell density in cultures at the beginning of the 
treatment, for example, can be of crucial importance 
for AE eff ectiveness. While in low-density cultures AE 
was effi  cient in the range from 20 to 40 μM, applied on 
the subconfl uent/confl uent state of the same cell type, 
it became completely ineffi  cient [9]. It means that in-
tracellular features previously declared as essential for 
the sensitivity to the treatment with AE easily become 
irrelevant when cells reached the confl uence. Close 
intercellular contact dramatically aff ected AE infl u-
ence on the tumor cells in vitro, making questionable 
compound eff ectiveness in vivo. Since AE potential to 
reduce tumor volume in vivo was already documented 
[16,34], it is clear that the spectrum of its infl uence on 
tumor progression is more complex than it is possible 
to be simulated in vitro.  Loss of AE potential to direct-
ly aff ect tumor cell viability in confl uent cell cultures 
was discovered by the case in experiments designed 
in order to explore its eff ectiveness in the presence of 
proinfl ammatory cytokines in rat astrocytoma C6 and 
mouse fi brosarcoma L929 cell cultures [9]. Namely, the 
presence of proinfl ammatory cytokines in mentioned 
cell cultures triggered production of endogenous ni-
tric oxide (NO) through enhanced expression of iNOS. 
To quantify NO and to determine the AE infl uence on 
its production, cells were exposed to the compound 
when they were in the high-density state. In addition 
to the fact that AE remarkably inhibited iNOS expres-
sion and NO production in the presence of cytokine 
stimulation, it becomes clear that even unstimulated, 
but AE treated cells were insensitive to the treatment 
when the drug is applied on subconfl uent/confl uent 
culture, oppositely to their low-density counterpart. 
Furthermore, generated NO negatively regulates vi-
ability of its own producers – C6/L929 cell, through 
induction of apoptosis. This mechanism is known as 
suicidal and is established by our immune cells and 
their products- proinfl ammatory cytokines, as a part 
of a defensive mechanism against the tumor. Under 
these circumstances, the iNOS inhibiting the potential 
of AE consequently abolished interleukin 1(IL1)/inter-
feron-γ (IFNγ) antiglioma and antifi brosarcoma eff ects 
(Scheme 1A). Not too far, our group discovered that 
AE neutralizes tumoricidal potential of tumor necro-
Scheme 1. Interplay of AE with cytokines in tumor microenvi-
ronment. A) AE inhibited on IL1/IFNγ triggered NO producti-
on in tumor cells. B) AE diminished TNFα mediated tumorici-
dal action.
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sis factor α (TNFα) through induction of autophagy, 
which opposes to TNFα mediated apoptosis (Scheme 
1B) [21]. In addition, since ERK1/2 is very important for 
the propagation of TNFα triggered signal, diminished 
activation of this protein upon AE became, at least 
partly, responsible for the observed tumor protective 
activities of the agent. Here we arrived to one more 
paradoxical level of antitumor/protumor potential of 
AE, facing with the fact that same signal, like the in-
hibition of ERK1/2, mediates both- tumor destructive 
activities such as blockage of proliferation, induction of 
diff erentiation and even chemo-sensitization, and con-
comitantly, seriously opposes to some of the import-
ant cytokine-mediated aspects of antitumor immune 
response. A long list of contradictions is further ex-
tended by AE infl uence on macrophages (Mf) (Scheme 
2). In concordance with its ability to down-regulate 
iNOS expression and NO production in C6 and L929 
cells, as well as their healthy counterpart- astrocytes 
and fi broblasts, cultivation of Mf in the presence of 
the drug resulted in suppression of NO release [35]. 
This result indicated the diminished antitumor capac-
ity of Mf when they are exposed to AE. Instead of this, 
co-cultivation of macrophages with glioma cells in the 
presence of AE revealed even enhanced the cytotoxic 
potential of Mf and, concordantly, enhanced nitrite ac-
cumulation in culture supernatants, as a consequence 
of the increased release of NO. The observed contradic-
tion between AE infl uence on Mf NO production when 
cells were cultivated alone and in co-cultures with tu-
mor cells can be connected with some additional sig-
nal generated from the contact between tumor cells 
and Mf, which in combination with AE resulted in hy-
per- instead of hypo-production of NO. However, the 
same eff ect was observed in high-density cultures of 
peritoneal Mf alone, indicated ones more, the pivotal 
importance of cell to cell contact and its infl uence on 
signals triggered with AE. Importantly and diff erently 
to the eff ect of AE on NO production determined in C6/
L929 cells as well as primary astrocytes and fi broblasts, 
hyper-production of NO observed in the high-den-
sity culture of mouse Mf was iNOS independent and 
resistant to treatment with inhibitors of transcription 
or translation, actinomycin, and cycloheximide, respec-
tively [35, unpublished data]. It is clear that AE is able 
to interfere with NO production at the level of iNOS 
gene as well as protein expression. In addition to NO, 
it was discovered that AE down-regulated production 
of interleukin-6 and interleukin-1β in macrophage cell 
line RAW264.7 cells upon stimulation with bacterial li-
popolysaccharide and realized the suppressive eff ect 
on leukocytes isolated from Sprague-Dawley rats, de-
creasing the phagocytic potential of Mf and NK cells 
activity. Contradictory, measurement of cytokine pro-
duction showed that AE augmented the interleukin-1 
β and TNFα [36,37]. Altogether, it is clear that outcome 
of the treatment with AE presents the net eff ect of the 
complex network of hardly predictable interactions 
generated through collection of signals triggered at 
the level of DNA and genes, proteins and cell mem-
brane. More than that, further integration of the stimuli 
modifi ed by AE happens in communication between 
diff erent cells in heterogeneous tumor mass- tumor 
cells in the diff erent stage of diff erentiation and their 
non-transformed counterparts, stromal cells, and var-
ious immune cells. 
INTERPLAY WITH CYTOSTATIC DRUGS: FROM 
SYNERGISM TO ANTAGONISM
Usage of aloe derived anthraquinones as chemosen-
sitizing agents are well described in the literature. 
Mostly literature data evaluate the eff ect of emodin 
as an amplifi er of chemotherapy, especially cisplatin. 
The interaction with the drug basically refers to ROS 
production and their sensitizing features, interference 
with multi-drug resistant transporters and induction 
of autophagy [38,39]. Even though the antitumor 
action of AE is well studied there are only a few pa-
pers describing its interaction with chemotherapeutic 
drugs. The co-treatment of Merkel cell carcinoma with 
cis-platinol (abiplastin), doxorubicin (adriablastin), and 
5-fl uorouracil (5-Fu), and AE resulted in potentiation of 
their cytotoxicity [40]. Similarly, AE amplifi ed the cyto-
toxicity of tamoxifen against MCF-7 breast cancer cells 
through reduction of epidermal growth factor recep-
tor (EGFR), rat sarcoma (Ras), ERK, c-Myc, and mTOR 
protein expression. In addition, the activity of Ras/
ERK and phosphatidylinositol 4,5-bisphosphate 3-ki-
nase (PI3K)/mTOR pathways was suppressed. Produc-
tion of ROS and enhanced cell death in co-treatment 
was potentiated indicating that AE can act as a strong 
chemosensitizer [41] The potentiation of 5-fl uorouracil 
was also achieved in epidermoid carcinoma A431 and 
head and neck squamous cell carcinoma SCC25A431 
through regulation of caspase-8, -9, and -3 expression 
Scheme 2. Infl uence of AE on macrophage NO production 
depending on cell-cell contact. AE inhibited NO production 
in low-density macrophage cultures while in high-density or 
in co-cultivation with tumor cells hypo production of NO is 
converted to hyper production.
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[42]. Oppositely to the benefi cial chemosensitizing ef-
fect of AE, there are few data indicating opposite ef-
fect. The possibility that the concomitant application 
of AE and certain cytostatic can lead to neutralization 
of tumoricidal eff ects of chemotherapy, underlines 
that special caution is needed in the eventual design 
of combined treatment with conventional drugs. We 
already described that AE as a single agent possesses 
strong antitumor potential on two diff erent melanoma 
cell lines, human A375 and mouse B16. However, par-
allel treatment with doxorubicin or paclitaxel resulted 
in antagonistic action in vitro [11]. In line with this, AE 
neutralized cisplatin-induced apoptosis and necrosis 
on murine L929 fi brosarcoma and C6 glioma cell lines. 
The counteracted action of cisplatin was due to op-
posite regulation of ERK in tumor cells, but not c-Jun 
N-terminal kinase [43]. 
ALOE EMODIN AS A SENSITIZER IN 
PHOTODYNAMIC THERAPY 
Photodynamic therapy (PDT) is a clinically approved, 
noninvasive therapeutic method that includes the ap-
plication of a photosensitizing agent concomitantly 
with a particular type of light [44]. This procedure can 
be valuable particularly for early-stage tumors but also 
can extend survival and quality of life of patients with 
inoperable cancers. Its advantage is marginal toxicity 
for normal tissues, minor systemic eff ects, diminished 
morbidity and development of resistance mechanisms. 
Photosensitizing substances are activated by a specifi c 
wavelength that usually triggers the production of ROS 
that is harmful to cancer cells. Besides the direct killing 
of cancer cells, such treatment aff ects blood vessels in 
the tumor and triggered an immune response against 
the tumor. Also, repetition of PDT and concomitant 
treatment with surgery, radiation, and chemotherapy 
is possible. So far, PDT is approved by the Food and 
Drug Administration for the treatment of esophageal 
cancer and non-small cell lung cancer. Recent fi ndings 
indicate that AE can be a useful drug as photosensi-
tizer during PDT. Therefore, it was shown that AE, as 
the part of this therapeutic approach, inhibited prolif-
eration of oral mucosa carcinoma KB cells in G1 phase 
and triggered apoptotic cell death due to the massive 
ROS production. Apoptotic cell death was followed 
with an up-regulated expression of caspase-3 and Bax 
together with strong suppression of Bcl-2 expression. 
Moreover, AE-PDT had marked inhibitory eff ect in vivo 
and extended the survival time of animals without no-
table side eff ects [45]. Similar fi ndings were observed 
in human gastric cancer SGC-7901 cells where the 
AE-induced PDT resulted in the activation of mitochon-
drial-dependent apoptosis [46]. Apoptosis is also the 
main outcome of AE-PDT of osteosarcoma MG63 cells. 
Fast intracellular ROS production led to the disruption 
of mitochondrial membrane potential, the release of 
cytochrome c, enhancement of caspase-3, -9, and -12, 
CCAAT-enhancer-binding protein homologous protein 
(CHOP) and glucose-regulated protein 78 (GRP78) [47]. 
Apart from apoptosis, AE-PDT induced the autopha-
gy of human osteosarcoma cell line MG-63 through 
the activation of the ROS-JNK signaling pathway [48]. 
In addition, AE as a sensitizer for PDT interferes with 
the metastatic spreading of MCF-7 breast cancer cells. 
Oxidative stress targeted the expression of MMP2, 
MMP9, VEGF, and nuclear factor (erythroid-derived 2)-
like 2 (Nrf2) as well as cytoskeleton organization after 
treatment with AE-PDT [49]. In lung cancer, H460 cells 
photo-activated AE provoked a disturbance of cyto-
skeleton and triggered anoikis, as the programmed cell 
death that occurs in adherent cells detached from the 
extracellular matrix. Anoikis is related to α-actinin and 
MAPK expression and led to the mitochondrial perme-
ability transition pore opening and elevated expres-
sion of apoptosis-related proteins [50]. Aloe emodin 
and irradiation stimulated the expression of protein 
kinase Cδ (PKCδ) in H460 cells and its translocation of 
to the nucleus. Additionally, AE-PDT triggered numer-
ous proteins important for cytoskeleton organization 
like RAS, ras homolog gene family member A (RHO), 
p38, heat shock protein 27 (HSP27), focal adhesion ki-
nase (FAK), α-actinin and tubulin [51]. Finally, AE-PDT 
interfered with angiogenesis process that is crucial for 
both growth and metastatic spreading of cancers. Aloe 
emodin photodynamic therapy suppressed formation 
branching points, tubule number, and length. Also, 
the number of capillary structures was signifi cantly re-
duced by AE-PDT treatment. Migration and invasion of 
human umbilical vein endothelial cells were also aff ect-
ed by the treatment. Mention processes are connected 
with the activation of p38, ERK, but not JNK, while the 
expression of vascular endothelial growth factor was 
diminished upon the treatment. In addition, AE-PDT 
altered the organization of F actin cytoskeleton [52].
NEW CHEMICAL DESIGNS FOR IMPROVEMENT OF 
AE ANTICANCER POTENTIAL
The antitumor activity of AE is highly compromised by 
its rapid degradation and low bioavailability. A lot of 
eff ort was made to make a diff erent formulation of AE 
to improve its features. One of the approaches includes 
the application of nanotechnology. Wu et al. made a 
poly (lactic-co-glycolic acid) based AE nanoparticles. 
The application of AE in this form was more effi  cient 
than an original compound in inhibition of human 
lung squamous cell carcinoma proliferation, induction 
of cell cycle arrest and further apoptotic cell death. 
Apoptosis was followed with activation of Caspase-3, 
poly (ADP-ribose) polymerase (PARP), Caspase-8 and 
Caspase-9. In parallel, ROS production was elevated. 
Nano-AE stimulated MAPK activation and suppressed 
PI3K/AKT signaling pathway. More importantly, na-
no-AE suppressed the tumor growth in vivo with in-
signifi cant toxicity [53]. The other group prepared 
surface-functionalized polyethylene glycol liquid crys-
talline nanoparticles (PEG-LCNPs) of AE to enhance its 
water solubility and enable its anticancer use. Particle 
size was 190 nm and their stability in serum was ele-
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vated. Further studies showed a good safety profi le of 
PEG-LCNPs of AE [54]. One more strategy involves solid 
lipid nanoparticles with a stable particle size at approx-
imately 90 nm with good drug entrapment effi  ciency 
and stability. AE loaded in solid lipid nanoparticles 
displayed amplifi ed cytotoxicity against human breast 
cancer MCF-7 cells and human hepatoma HepG2 cells 
in comparison to the AE. The toxicity toward human 
mammary epithelial MCF-10A cells was diminished. 
AE loaded in solid lipid nanoparticles induced apop-
tosis in MCF-7 cells probably due to increased cellular 
uptake of AE [55]. Similar improvement was achieved 
by integrating AE into the liposomal formulation. That 
formulation augmented cell death of A431 and SCC25 
cells and improved transdermal delivery of AE [42]. 
Other approaches aimed to make water-soluble for-
mulation consider the chemical modifi cation through 
coupling with various amino acid esters and substitut-
ed aromatic amines. Derivate signifi cantly reduced the 
growth of human liver cancer cells HepG2, and lung 
cancer cells NCI-H460, human epithelial carcinoma 
cells HeLa and prostate cancer cells PC3 more potently 
than AE alone [56]. The attachment of an amino-sugar 
unit to AE formed a new class of AE glycosides (AEGs) 
with improved cytotoxic potential even in doxorubi-
cin-resistant cell lines probably through interference 
with P-glycoprotein effl  ux pumps [57]. Finally, with an 
attempt to improve tumoricidal potential hybrid mole-
cule from rhein and AE was synthesized. This chimeric 
molecule was more effi  cient against human hepato-
ma HepG2, human nasopharyngeal carcinoma CNE, 
human lung cancer NCI-H460, human ovarian cancer 
SK-OV-3, and human cervical cancer HeLa cells than 
separate compounds [58].  
CONCLUSION
Summarizing all the mentioned eff ects of AE, it is cle-
ar that its direct tumoricidal potential and synergistic 
action with some of the conventional drugs is undo-
ubting (Scheme 3). However, it is not possible to over-
view it separately and independent from the other ac-
tors in tumor microenvironment or applied therapy. It 
is more than clear that serious observation is necessary 
because the line between the cure and harm is so tiny 
and hard to predict. “Magic bullet” for cancer therapy 
still not exists but the defi nition of conditions and pro-
tocols when the phytotherapeutics can be benefi cial is 
highly valuable. Thousands of years old ethnic- medi-
cine can defi nitely mark the right way, but gathering 
an experimental knowledge and clinical experience is 
also necessary. The study of Lissoni et. on 240 patients 
with metastatic lung, colorectal and pancreatic tumors 
who have received chemotherapy in parallel with Aloe 
arborescens treatment showed signifi cant tumor re-
gressions, disease control and increased survival rate, 
claiming that this class of drugs might have a clinical 
potential [59]. We can have multiple benefi ts from 
phytotherapy if we understand and utilize it correctly.
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ALOE EMODIN U TRETMANU TUMORA: SAVEZNIK ILI PROTIVNIK
Kratak sažetak
Loš odgovor visoko invazivnih formi kancera na tretman se ne može obja-
sniti samo fenotipom ćelija rezistentnih na indukciju smrti već i repopulaci-
jom tumora u odgovoru na oštećenja nastala usled primene hemio- ili ra-
dioterapije. Ozbiljna ograničenja regularnih terapeutskih pristupa jedan su 
od glavnih izazova za biologe da utvrde relevantnost i istraže mehanizme 
u osnovi lečenja malignih bolesti zasnovanih na tradicionalnoj medicini. 
Jedna od najstarijih i najmoćnijih biljaka sa 4000 godina dugom tradicijom 
u narodnoj medicini, Aloe vera, je intenzivno izučavana u poslednjem veku 
zbog čitave riznice aktivnih komponenti privlačnih kako lekarima i pacijen-
tima, tako i naučnicima. Antrahinoni, emodin i aloe emodin (AE), izolovani 
iz Aloe vera i drugih biljaka iz porodice Polygonaceae su defi nitivno najvi-
še izučavani konstituenti. Aloe emodin poseduje vešestruka antitumorska 
svojstva realizovana kroz indukciju zastoja u ćelijskom ciklusu, ćelijske smr-
ti, diferencijacije i supresije motiliteta malignih ćelija. Međutim, njegova in-
terakcija sa tumorskom ćelijom nije jednosmerna i zbog kompleksne mreže 
signala u mikrosredini tumora može lako biti konvertovana sa destruktivne 
u promovišuću za tumor. Ovaj pregledni članak će sumirati direktne tumo-
ricidne efekte ali će razmatrati i interakcije AE sa imunskim ćelijama i njiho-
vim medijatorima. Takođe, biće elaboriran i potencijal AE kao hemio- i fo-
tosenzitizatora. Konačno, diskutovaće se i novi pristupi u modifi kaciji ovog 
molekula koji uključuju hemijske intervencije i primenu nanotehnologije. 
Ključne reči: Aloe emodin, antikancerska svojstva, interakcija sa mikrosre-
dinom, citostatici, fotodinamička terapija 
Sanja Mijatović, Danijela 
Maksimović-Ivanić
Odeljenje za imunologiju, Institut za 
biološka istraživanja “Siniša Stanković”, 
Univerzitet u Beogradu, Srbija.
Autor za korespondenciju:
dr Sanja Mijatović
Adresa: Institut za biološka istraživanja  
„Siniša Stanković”, Bulevar despota Stefana 
142, 11000 Beograd, Srbija; 
E-mail: sanjamama@ibiss.bg.ac.rs
Tel.: +381 11 2078 452;
Faks: +381 11 2761 433.
